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A B S T R A C T
The effects of pre-treatment with vatinoxan (MK-467) on dexmedetomidine-induced cardiopulmonary
alterations were investigated in sheep. In a crossover study design with a 20-day washout, seven sheep
were anaesthetised with sevoﬂurane in oxygen and air. The sheep were ventilated with the pressure-
limited volume-controlled mode and a positive end-expiratory pressure of 5 cmH2O. Peak inspiratory
pressure (PIP) was set at 25 cmH2O. The sheep received either 150 mg/kg vatinoxan HCl (VAT + DEX) or
saline intravenously (IV) 10 min before IV dexmedetomidine HCl (3 mg/kg, DEX). Cardiopulmonary
variables were measured before treatments (baseline), 3 min after vatinoxan or saline, and 5, 15 and
25 min after dexmedetomidine. Computed tomography (CT) of lung parenchyma was performed at
baseline, 2 min before dexmedetomidine, and 10, 20 and 30 min after DEX. Bronchoalveolar lavage (BAL)
was performed after the last CT scan and shortly before sheep recovered from anaesthesia. After VAT,
cardiac output signiﬁcantly increased from baseline. DEX alone signiﬁcantly decreased partial arterial
oxygen tension, total dynamic compliance and tidal volume, whereas PIP was signiﬁcantly increased.
With VAT + DEX, these changes were minimal. No signiﬁcant changes were detected in haemodynamics
from baseline after DEX. With VAT + DEX, mean arterial pressure and systemic vascular resistance were
signiﬁcantly decreased from baseline, although hypotension was not detected. On CT, lung density was
signiﬁcantly increased with DEX as compared to baseline. No visual abnormalities were detected in
bronchoscopy and no differences were detected in the BAL ﬂuid after either treatment. The
pre-administration of vatinoxan alleviates dexmedetomidine-induced bronchoconstriction, oedema
and hypoxaemia in sevoﬂurane-anaesthetised sheep.
© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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In veterinary clinical practice, α2-adrenoceptor agonists are
used as sedatives, anxiolytics and analgesics, and to reduce general
anaesthetic requirements. However, in all species, their use is
associated with a number of side effects, most notably bradycardia,
vasoconstriction and a reduction in cardiac output. These negative
side effects are mainly mediated via peripherally located
α2-adrenoceptors (Bryant et al., 1998).* Corresponding author at: Department of Equine and Small Animal Medicine,
Faculty of Veterinary Medicine, Koetilantie 2, P.O. Box 57, 00014 University of
Helsinki, Helsinki, Finland.
E-mail address: magdy.adam@helsinki.ﬁ (M. Adam).
https://doi.org/10.1016/j.tvjl.2018.07.007
1090-0233/© 2018 The Author(s). Published by Elsevier Ltd. This is an open access artiIn small ruminants, particularly sheep, α2-agonists are known
for the induction of arterial hypoxaemia. The intensity of
hypoxaemia depends on a number of factors, such as the dose
of the agonist, route of administration, age of the animal and
inter-individual variation. However, the hypoxaemic effect
of α2-agonists in sheep is primarily mediated via the peripheral
α2-adrenoceptors (Celly et al., 1997). The exact underlying
mechanism(s) remain debated among researchers, although
several theories have been proposed. Xylazine caused the
contraction of isolated sheep tracheal strips (Papazoglou et al.,
1995) and increased airway pressure in halothane-anaesthetised
sheep (Nolan et al., 1986; Papazoglou et al., 1994). The authors
hypothesised that the increased airway pressure was either due to
decreased dynamic compliance or increased airway resistance
(Nolan et al., 1986; Papazoglou et al., 1994). In addition, pulmonarycle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pulmonary microembolism (Eisenach, 1988), pulmonary venom-
otor spasm (Bacon et al., 1998), the release of inﬂammatory
mediators due to the activation of intravascular pulmonary
macrophages (Celly et al., 1999a) and increased hydrostatic
pressure (Kästner et al., 2007) have also been suggested as the
cause of hypoxaemia.
In sevoﬂurane-anaesthetised sheep, dexmedetomidine induced
marked vasoconstriction, with increases in systemic and pulmo-
nary arterial blood pressure, pulmonary occlusion pressure and
capillary wedge pressure (Kästner et al., 2005, 2007; Kutter et al.,
2006). Furthermore, decreased dynamic compliance, increased
airway resistance and an increased pulmonary shunt fraction and
dead space ratio were also reported (Kästner et al., 2005, 2007;
Kutter et al., 2006).
Vatinoxan (previously named MK-467 and L-659,066) is a
peripheral α2-adrenoceptor antagonist that poorly penetrates the
mammalian central nervous system due to its low lipophilicity
(Clineschmidt et al., 1988). Vatinoxan has demonstrated an ability
to alleviate the adverse cardiopulmonary effects associated with
dexmedetomidine in various species, whilst preserving the
desired, centrally mediated actions (Raekallio et al., 2010;
Honkavaara et al., 2008, 2011, 2017). The aim of the present study
was to investigate the ability of vatinoxan to alleviate the adverse
cardiopulmonary alterations induced by dexmedetomidine in
sevoﬂurane-anaesthetised sheep. Our hypothesis was that pre-
treatment with vatinoxan would prevent the increase in airway
resistance and pulmonary oedema formation, and consequently
reduce the degree of induced hypoxaemia following dexmedeto-
midine administration.
Materials and methods
Animals
A prospective, randomised, cross-over design was used with a minimum
washout period of 20 days between treatments. Seven Texel and Crossbred sheep,
1–3 years of age, with previously exteriorised right carotid arteries and a
mean  standard deviation (SD) body weight of 55  4 kg were used in this study.
The animals were deemed healthy based on physical examination, haematology and
blood chemistry results. Food was withheld for 24 h prior to each phase of
anaesthesia. The study was approved by the national Animal Experiment Board of
Finland (license number ESAVI/9394/04.10.07/2015; date of approval 12th January
2016).
Induction and maintenance of anaesthesia
Following the placement of an 18 G cephalic catheter (Terumo), anaesthesia was
induced with propofol (Vetofol 10 mg/mL; Norbrook Laboratories) until effect. After
endotracheal intubation with a silicone endotracheal tube (9–11 mm internal
diameter, MILA International), anaesthesia was maintained at 3.0% end-tidal
sevoﬂurane (SevoFlo; Abbott Laboratories) in 50% oxygen and air (0.5 fraction of
inspired oxygen (FiO2)). The sheep were positioned in sternal recumbency and
intermittent positive pressure ventilation (IPPV) was started immediately following
intubation with the pressure-regulated volume-controlled (PRVC) mode (Perseus A
500, Dräger); the positive end-expiratory pressure (PEEP) was set at 5 cmH2O and
maintained at a constant level throughout the anaesthesia. Peak inspiratoryFig. 1. Experimental timeline. BAL, bronchoalveolar lavage; BL, baseline measurements
dexmedetomidine administration; VAT, vatinoxan.pressure (PIP) was set initially at 25 cmH2O and, if required due to a decrease in
pulmonary compliance, increased to 30 cmH2O to achieve a tidal volume (VT) of
12 mL/kg and an end-tidal carbon dioxide concentration (ETCO2) of 40 mmHg. At
the beginning of anaesthesia, an inspiratory-expiratory ratio (I:E) of 1:2 and
respiratory rate (fR) of 11–13 breaths per min were set, but they were adapted as
necessary during the anaesthetic to maintain normocapnia. Parameters monitored
and recorded every 5 min were rectal temperature, haemoglobin oxygen saturation
(SpO2), pulse rate (Nonin PalmSAT 2500 series), fR, FiO2, ETCO2, end-tidal
sevoﬂurane, VT, minute volume (MV), total dynamic compliance (Cdyn mL/cmH2O)
and PIP. Airway gas concentrations were measured from the proximal end of the
endotracheal tube.
Instrumentation
The animals were instrumented with a right carotid arterial catheter (20 G; B.
Braun Melsungen AG), a right jugular catheter (16 G; MILA International) and a
pulmonary artery catheter (7 Fr, 110 cm, triple-lumen Swan-Ganz monitoring
catheter; Edwards Lifesciences) via the left jugular vein. The correct placement of
the pulmonary artery catheter was conﬁrmed by the shape of pressure waves and
subsequently conﬁrmed with CT. All catheters were secured in position with skin
sutures. Following instrumentation, a stomach tube was passed into the rumen.
Invasive arterial blood pressure (IBP), central venous pressure (CVP) and pulmonary
arterial pressure (PAP) were measured (Datex Engstrom S/5 monitor, Datex
Ohmeda) using pre-calibrated pressure transducers (Gabarith PMSET; Becton
Dickinson). The height at the shoulder joint was used as the zero reference point for
all blood pressure measurements. Cardiac output (CO) was measured using the
lithium dilution method (LiDCO plus Haemodynamic Monitor; LiDCO). Anaerobic
blood samples were obtained in pre-heparinised syringes (Pico50; Radiometer) for
arterial and mixed venous blood gas analysis and were placed in iced water for
immediate analysis (ABL 855; Radiometer). The blood gases were corrected
for rectal temperature. Blood samples for the determination of plasma dexmede-
tomidine and vatinoxan concentrations were collected from the carotid artery
catheter, centrifuged at 3000 g for 15 min, and frozen at 20 C until analysed.
Study protocol
Immediately after instrumentation, the animals were moved to the CT suite.
After baseline cardiopulmonary measurements and a baseline thoracic CT scan, an
intravenous (IV) bolus of either 150 mg/kg vatinoxan hydrochloride (vatinoxan HCl;
Vetcare), diluted in saline to achieve a concentration of 0.5%, or a similar volume of
saline was injected (T-10; VAT + DEX; DEX). All cardiopulmonary measurements
were repeated 3 min later (T-7), followed by a CT scan (T-2). After the second CT
scan, 3 mg/kg dexmedetomidine HCl (Dexdomitor 0.1 mg/mL, Orion Pharma)
diluted in 20 mL saline was injected IV over 30 s 10 min after vatinoxan or saline
(T0), and all cardiopulmonary measurements were repeated 5, 15 and 25 min after
dexmedetomidine (T5, T15 and T25). The CT scan was repeated at 10, 20 and 30 min
(T10, T20 and T30) after dexmedetomidine administration (Fig. 1).
The CT scan of the lungs (GE Lightspeed VCT 64, GE Healthcare) was performed
at 140 kV, mA noise index 18.0 (min 120 mA/max 710 mA), slice thickness
0.625 mm, time/rotation 0.4 sec and pitch 0.984. A lung algorithm was used and
all images were evaluated with a window level of 500 and window width of 1500.
The CT scanner was calibrated daily according to the hospital’s procedure. The
cross-sectional areas of the right caudal pulmonary artery and vein were measured
at the level of the proximal dorsocaudal branch of the vein according to Kästner
et al. (2007). Two regions of interest (ROI) of 0.5 cm2 were drawn on this same
image: one positioned dorsally (ROI 1), close to the periphery of the lung
parenchyma, and the other ventrolateral (ROI 2) to the main bronchus as shown in
Fig. 3A, and the CT values of each ROI were calculated as Hounsﬁeld units (HU). The
measurements were conducted three times with an interval of at least 1 week by an
investigator blinded to the treatments and time points, and the mean values were
used.
Bronchoscopy and bronchoalveolar lavage (BAL) were performed via the
endotracheal tube approximately 5 min after the last CT scan. Fifty millilitres of
saline was infused through the work channel of the bronchoscope (Olympus; CT, computed tomography; DEX, dexmedetomidine; S, saline; T-10, 10 min before
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lobes, and the ﬂuid was immediately withdrawn and placed on ice. The BAL ﬂuid
was ﬁltered through a gauze, after which the quantity of white blood cells was
calculated and differential counts were made from cytocentrifuge smears stained
with May-Grünwald Giemsa.
At the end of the study, anaesthesia was discontinued and the sheep received
0.5 mg/kg meloxicam (Metacam 20 mg/mL, Boehringer Ingelheim Vetmedica) IV
and 0.03 mg/kg atipamezole HCl (Alzane 5 mg/mL, Syva Laboratories SA) IM prior to
the removal of the instrumentation and tracheal extubation. Supplemental oxygen
at a rate of 10 L/min was provided by face mask until the sheep had fully recovered.
Dexmedetomidine and vatinoxan plasma concentrations were analysed as
described previously (Adam et al., 2018); 50 mL of plasma were precipitated on a
Sirocco plate with 250 mL of internal standard solution in acetonitrile (containing
100 ng/mL of propranolol and 20 ng/mL of chlorpromazine). After vigorous mixing
for 5 min at 1350 revolutions per min, the samples were centrifuged for 20 min at
2952 g. Then, 50 mL were transferred to a UPLC 96-well plate, diluted with 450 mL of
20% acetonitrile and analysed. The standard samples were prepared in blank sheep
plasma by spiking into concentrations of 0.02–20,000 ng/mL of the analytes, while
the quality control samples were prepared by spiking the blank sheep plasma into
concentrations of 0.2, 2, 20, 200 and 2000 ng/mL. Analyses were carried out with
liquid chromatography-mass spectrometry (Waters Acquity UPLC, Waters TQ-S
triple-quadrupole MS, Waters Corporation) using a C18 column (2.1 50 mm,
1.7 mm) with a guard ﬁlter (Waters Corporation). The quantiﬁcation ranges (ng/mL),
accuracy (%) and precision (%) for vatinoxan and dexmedetomidine were 2–2000,
96–105, 6.8–13 and 0.2–200, 92–102 and 4.1–9.7, respectively.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics Version 24.0 for
Windows. The assumption of normality was evaluated with the Shapiro–Wilk test.
Cardiopulmonary variables were analysed using a generalised linear mixed model
with time, treatment and their interactions as ﬁxed effects, and animal, time-by-
animal and treatment-by-animal as random effects. Sequential Bonferroni
corrections were used to adjust for multiple comparisons where appropriate.
The CT measurements were compared against their baselines and between
treatments with the Wilcoxon Signed-Rank test. P values < 0.05 were considered to
be signiﬁcant.
Results
Cardiopulmonary variables are presented as the mean  SD
(Tables 1 and 2; Fig. 2A–D). There were no signiﬁcant differences
between treatments in heart rate (HR), mean pulmonary artery
pressure (MPAP) or mean central venous pressure (MCVP).
However, with VAT + DEX, the mean arterial pressure (MAP) and
systemic vascular resistance (SVR) were signiﬁcantly decreased at
T15 and T25 compared to the baseline and to DEX. With DEX, the
partial pressure of arterial oxygen (PaO2), partial pressure of
venous oxygen (PvO2) and total dynamic compliance (Cdyn) were
signiﬁcantly decreased from the baseline at T5 and T15. At theTable 1
Mean  standard deviation (SD) of cardiopulmonary haemodynamics in seven sheep tha
received 3 mg/kg dexmedetomidine (DEX).
Treatment 
BL T-7 
HR (bpm) DEX 84  16 84  1
VAT + DEX 82  8 85  6
MAP (mmHg) DEX 92  17 95  1
VAT + DEX 94  10 90  8
MPAP (mmHg) DEX 18  3 18  3
VAT + DEX 20  2 19  3
MCVP (mmHg) DEX 10  3 9  2 
VAT + DEX 13  4 11  3
CO (L/min) DEX 2.87  0.78 3.15 
VAT + DEX 2.77  0.26 3.63 
SVR (dynes/s/cm5) DEX 2328  440 2279 
VAT + DEX 2363  442 1784 
SV (mL/kg) DEX 34.1  4.1 37.3 
VAT + DEX 34.2  3.9 42.9 
BL, baseline; bpm, beats per min; HR, heart rate; MAP, mean arterial pressure; MPAP, m
output; SVR, systemic vascular resistance; SV, stroke volume.
† Signiﬁcant difference between treatments.
* Signiﬁcantly different from BL (P < 0.05).same time, PIP, partial pressures of arterial (PaCO2) and venous
(PvCO2) CO2, and ETCO2were signiﬁcantly higher than the baseline
after DEX. No signiﬁcant changes from the baseline were observed
in these variables after VAT + DEX.
No abnormal patterns were detected in the pulmonary
parenchyma in baseline CT scans. No signiﬁcant changes compared
to the baseline were detected in the cross-sectional area of the
caudal pulmonary vein throughout the observation period after
either treatment. However, the caudal pulmonary vein area was
signiﬁcantly larger at T-2 and T10 with VAT + DEX compared to
DEX. With VAT + DEX, the cross-sectional area of the caudal
pulmonary artery was signiﬁcantly smaller compared to baseline
measurements at T30, and compared to DEX, it was smaller at T20
and T30. The CT values for ROI 1 remained within the baseline
values after both treatments, whereas the values for ROI 2 were
signiﬁcantly increased with DEX at T20 and T30, and signiﬁcantly
decreased with VAT + DEX at T30, compared to baseline measure-
ments (Table 3; Fig. 3).
No excessive bronchial mucus or oedema was seen in the
bronchi (Fig. 4), and no visual abnormalities were detected in the
BAL ﬂuid after either treatment. The amount and differential
analysis of white blood cells in the BAL ﬂuid did not signiﬁcantly
differ between the treatments.
The plasma concentrations of dexmedetomidine and vatinoxan
are presented in Fig. 5A–B. There were no signiﬁcant differences in
dexmedetomidine concentrations between treatments.
Discussion
After DEX alone, PaO2, VT and Cdyn were signiﬁcantly lower,
whereas PIP, PaCO2 and lung density were signiﬁcantly increased,
compared to baseline. Pre-treatment with vatinoxan prevented
these negative changes.
In the present study, the role of the vascular component and
pulmonary congestion appears to have been minimal in the
development of the unwanted changes in airway dynamics. No
changes were observed in systemic or pulmonary circulation after
DEX, consistent with the earlier ﬁndings in sheep (Celly et al.,
1999b; Talke et al., 2000). However, Cdyn decreased, and we suggest
that the increased airway resistance, indicated by the reduced VT
and the increased pressure required to deliver the VT, was a
reﬂection of bronchoconstriction mediated by α2-adrenoceptors.
In sheep, xylazine at a dose of 200 mg/kg IV induced a signiﬁcantt were pre-treated with 150 mg/kg vatinoxan (VAT + DEX) or saline and 10 min later
Time (min)
T5 T15 T25
6 74  9 75  11 76  11
 76  9 73  8 73  9
3 100  8 97  10† 81  6†
 96  4 75  4* 69  5*
 21  4 20  3 18  5
 19  2 20  5 17  2
13  2 11  2 10  3
 12  4 11  3 11  3
 0.72 2.82  0.52 3.05  0.31 3.37  0.25
 0.69* 3.25  0.68 3.04  0.41 3.15  0.44
 260† 2547  550 2256  262† 1676  203*
 306* 2121  396 1678  180* 1480  119*
 4.3 37.3  8.0 41.5  8.1 45.2  7.7
 9.9 43.1  8.5 41.6  3.7 43.2  4.0
ean pulmonary arterial pressure; MCVP, mean central venous pressure; CO, cardiac
Table 2
Mean  standard deviation (SD) of blood gas analyses in seven sheep that were pre-treated with 150 mg/kg vatinoxan (VAT + DEX) or saline and 10 min later received 3 mg/kg
dexmedetomidine (DEX).
Treatment Time (min)
BL T-7 T5 T15 T25
PaO2 (mmHg) DEX 289  23 280  30 195  85* 213  78* 259  37
VAT + DEX 280  36 288  23 289  23† 289  19† 291  16†
PaCO2 (mmHg) DEX 37  2 37  1 44  8* 43  5* 41  3
VAT + DEX 36  3 37  1 37  2† 38  2† 37  1
pHa DEX 7.53  0.03 7.54  0.02 7.48  0.08 7.50  0.05 7.51  0.03
VAT + DEX 7.53  0.02 7.54  0.03 7.54  0.03 7.54  0.03 7.55  0.03
SpO2 (%) DEX 99.9  0.4 99.7  0.5 98  3.3 99.6  0.5 99.6  0.5
VAT + DEX 99.7  0.5 99.7  0.5 99.7  0.5 99.7 0.5 99.6  0.8
PvO2 (mmHg) DEX 43  11 42  10 35  7* 37  5* 39  5
VAT + DEX 41  7 48  9 41  7† 42  7† 42  7
PvCO2 (mmHg) DEX 45  4 45  2 48  5 50  4* 50  3*
VAT + DEX 43  5 43  2 44  2 45  5† 45  2†
Hb (g/dL) DEX 7.7  0.8 7.4  0.8 7.5  0.8 7.6  0.8 7.5  0.8
VAT + DEX 7.9  0.7 7.8  0.9 7.6  0.8 7.5  0.8 7.3  0.8
BL, baseline; PaO2, partial oxygen pressure in arterial blood; PaCO2, partial carbon dioxide pressure in arterial blood; pHa, arterial pH; SpO2, haemoglobin oxygen saturation;
PvO2, partial oxygen pressure in mixed venous blood; PvCO2, partial carbon dioxide pressure in mixed venous blood; Hb, haemoglobin.
† Signiﬁcant difference between treatments.
* Signiﬁcantly different from BL (P < 0.05).
Fig. 2. Mean  standard deviation (SD) of (A) tidal volume (VT), (B) peak inspiratory pressure (PIP), (C) total dynamic compliance (Cdyn) and (D) end-tidal carbon dioxide (ET-
CO2) in sheep that were pre-treated with 150 mg/kg vatinoxan (VAT + DEX) or saline and 10 min later received 3 mg/kg dexmedetomidine (DEX). † Signiﬁcant difference
between treatments. * Signiﬁcantly different from baseline (BL; P < 0.05).
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of α2-adenoceptor antagonists idazoxan (Nolan et al., 1986) and
atipamezole (Papazoglou et al., 1994), but did not respond to
α1-adenroceptor antagonism with prazosin (Nolan et al., 1986).
Furthermore, xylazine caused a concentration-dependent contrac-
tion of isolated sheep tracheal strips, which was inhibited by
atipamezole but not by atropine (Papazoglou et al., 1995).In our study, an increased density of ROI 2 was observed in
thoracic CT images after DEX, but not after VAT + DEX. However,
our ﬁndings appeared to be less pronounced and they appeared
more slowly than those reported by Kästner et al. (2007). The
changes in vessel cross-sectional areas were also less than
previously described, despite the fact that we used a slightly
higher dose of dexmedetomidine (3 mg/kg IV) than Kästner et al.
Fig. 3. Transverse computed tomography images at the level of the mid-caudal lung lobes in a sheep that was pre-treated with 150 mg/kg vatinoxan (VAT + DEX) or saline and
10 min later received 3 mg/kg dexmedetomidine (DEX): at baseline (BL) and at 20 min (T20) (A, B; DEX), and at 2 min before (T-2) and at 20 min after (T20) dexmedetomidine
(C, D; VAT + DEX). Note that, in image (A), the arrows point to the caudal pulmonary vein (blue) and artery (red), whereas the circles 1 and 2 indicate the regions of interest
(ROI).
Table 3
Median (range) of computed tomography measurements cross-sectional area (cm2) of the caudal pulmonary artery and vein, and computed tomography values for two
regions on interest (ROI 1 and 2) in sevoﬂurane-anaesthetised sheep that were pre-treated with 150 mg/kg vatinoxan (VAT + DEX) or saline and 10 min later received 3 mg/kg
dexmedetomidine (DEX).
Treatment Time (min)
BL T-2 T10 T20 T30
Artery area (cm2) DEX 0.65 (0.57–0.95) 0.79 (0.61–1.00) 0.82 (0.61–1.10) 0.80 (0.76–1.03)† 0.78 (0.74–1.02)†
VAT + DEX 0.77 (0.61–0.99) 0.81 (0.58–0.96) 0.73 (0.64–0.94) 0.68 (0.59–0.93) 0.69 (0.57–0.90)*
Vein area (cm2) DEX 0.89 (0.63–1.25) 1.09 (0.63–1.33)† 1.05 (0.62–1.42)† 1.03 (0.70–1.47) 1.09 (0.66–1.38)
VAT + DEX 1.05 (0.67–1.46) 1.17 (0.67–1.58) 1.12 (0.65–1.56) 1.22 (0.67–1.68) 1.12 (0.69–1.44)
ROI 1 (HU) DEX 700 (755 to 650) 711 (753 to 632) 710 (758 to 651) 700 (761 to 641) 716 (771 to 651)
VAT + DEX 716 (761 to 646) 697 (728 to 660) 707 (755 to 666) 711 (759 to 684) 723 (771 to 685)
ROI 2 (HU) DEX 660 (681 to 515) 666 (689 to 532) 560 (-680 to 493) 604 (651 to 468)*,† 621 (659 to 460)*,†
VAT + DEX 617 (698 to 527) 609 (700 to 506) 638 (708 to 543) 641 (712 to 533) 640 (716 to 543)*
BL, baseline; HU, Hounsﬁeld units.
† Signiﬁcant difference between treatments.
* Signiﬁcantly different from BL (P < 0.05).
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during the bronchoscopy. Conversely, in the study of Kästner et al.
(2007), the post-mortem examination of sheep lungs withpulmonary oedema revealed that the trachea was ﬁlled with
foamy ﬂuid. Thus, Kästner et al. (2007) observed more severe
changes indicative of vascular congestion and pulmonary oedema
Fig. 4. Bronchoscopic views shortly before sheep recovered from anaesthesia. (A) 3 mg/kg dexmedetomidine at 10 min (DEX). (B) 150 mg/kg vatinoxan at baseline and 3 mg/kg
dexmedetomidine at 10 min (VAT + DEX). No excessive mucus, foam or oedema were observed in bronchi.
Fig. 5. Mean  standard deviation (SD) of (A) dexmedetomidine and (B) vatinoxan plasma concentrations in sheep that were pre-treated with 150 mg/kg vatinoxan
(VAT + DEX) or saline and 10 min later received 3 mg/kg dexmedetomidine (DEX).
68 M. Adam et al. / The Veterinary Journal 238 (2018) 63–69than we did. This inconsistency between the previous results and
ours might be due to high individual variation, not only between
sheep breeds, but also between individuals within the same breed.
In addition, we used PEEP during mechanical ventilation. In
experimental canine and porcine models of induced pulmonary
oedema, the use of moderate PEEP (10–20 cmH2O) limited the
increase in pulmonary extravascular ﬂuid (Fernández-Mondéjar
et al., 1996; Ruiz-Bailén et al., 1999), and signiﬁcantly improved the
gas exchange and decreased the shunt fraction as compared to zero
end-expiratory pressure (Wickerts et al., 1992). Although the PEEP
used in our study was only 5 mmH2O, it might have prevented
detectable vascular changes and limited the formation of pulmo-
nary oedema. Conversely, since the CT changes were in the ventral
part of lungs, this could partially explain the lack of changes in BAL,
which was performed from the dorsal and accessory lung lobes.
Additionally, the changes in CT could be due mainly to the
formation of interstitial rather than alveolar oedema. Overall, in
the present study, it seemed that the dexmedetomidine-induced
signiﬁcant reduction in PaO2 was probably caused by the
combination of bronchospasm and subsequent subclinical pulmo-
nary oedema. Pre-treatment with vatinoxan prevented both
unwanted effects.In the present study, MAP and SVR were signiﬁcantly lower
after VAT + DEX compared to the baseline and to DEX, whereas no
other systemic or pulmonary haemodynamic values differed
signiﬁcantly between treatments or from the baseline; however,
it is important to note that the administration of VAT + DEX did not
induce clinical hypotension. Our haemodynamic results more or
less agree with the ﬁndings reported after IV administration of
medetomidine in conscious (Talke et al., 2000) and halothane-
anaesthetised sheep (Celly et al., 1999b). In contrast, other groups
have reported a signiﬁcant increase from baseline in MPAP,
pulmonary artery occlusion pressure and capillary wedge pressure
after dexmedetomidine (2 mg/kg IV) administration in sevoﬂur-
ane-anaesthetised sheep (Kästner et al., 2005, 2007; Kutter et al.,
2006). One could suggest that hypoxic pulmonary vasoconstriction
played a role in the increased pulmonary vascular resistance
observed in previous studies; however, it is unlikely, since this
response is generally weak and variable in conscious sheep
(Ahmed et al., 1982, 1983), and would be expected to be blunted in
a dose-dependent manner in sevoﬂurane-anaesthetised sheep.
Individual variability in the response to α2-adrenoceptor
agonists is common amongst sheep. Wide individual variation
in the hypoxaemic response to medetomidine has been reported
M. Adam et al. / The Veterinary Journal 238 (2018) 63–69 69within a single ovine breed (Tulamo et al.,1995). Moreover, Kästner
et al. (2007) reported that, out of seven sevoﬂurane-anaesthetised
and mechanically ventilated sheep that received IV dexmedeto-
midine, one showed minimal pulmonary vasoconstriction and only
a transient and mild decrease in PaO2 during the study, whereas
the other six sheep responded to dexmedetomidine with
hypoxaemia and a signiﬁcant increase in pulmonary pressure. In
the present study, we also noticed substantial individual variabili-
ty, although none of our sheep became clinically hypoxaemic.
Speciﬁcally, in two individuals (both of the Texel breed), PaO2 was
more than halved from baseline with DEX alone, whereas the other
sheep (crossbred with Texel, Dorset and Gotland sheep) showed
only minor responses to the same treatment. The administration of
vatinoxan before dexmedetomidine prevented the decrease in
arterial oxygen tension in all individuals.
Conclusions
The pre-administration of vatinoxan alleviated dexmedetomi-
dine-induced bronchoconstriction and prevented the formation of
subclinical pulmonary oedema, a decrease in pulmonary dynamic
compliance and an increase in airway resistance in sevoﬂurane-
anaesthetised sheep. The cardiovascular effects of dexmedetomi-
dine were minimal and thus they did not appear to be responsible
for the decrease in PaO2 caused by dexmedetomidine.
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